Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
AssigneeBiogen Idec MA Inc.
InventorsDoreen LePage, Alan Gill
Life of this patent
Estimating the term…
Abstract
This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other chemotherapeutic agents, as well as therapeutic methods and screening methods for identifying agents that in combination with a lymphotoxin-beta receptor agonist agent have a supra-additive effect on tumor inhibition.
Claims47
A method for inhibiting tumor volume comprising administering an effective amount of a lymphotoxin-beta receptor (LT-β-R) agonist and an effective amount of at least one chemotherapeutic agent, wherein the administration of the LT-β-R agonist and the chemotherapeutic agent results in supra-additive inhibition of the tumor.
A method of treating cancer comprising administering an effective amount of a lymphotoxin-beta receptor (LT-β-R) agonist and an effective amount of a chemotherapeutic agent, which upon administration to a subject results in supra-additive inhibition of a tumor.
A pharmaceutical composition comprising an effective amount of a LT-β-R agonist, an effective amount of at least one chemotherapeutic agent, and a pharmaceutically acceptable carrier, which upon administration to a subject results in supra-additive inhibition of a tumor.
Dependencies are inferred from the claim text.